Document Type

Journal Article

Publication Title

European Association for Predictive, Preventive and Personalised Medicine (EPMA) Journal

Publisher

Springer

School

School of Medical and Health Sciences

RAS ID

31742

Funders

This work was partially supported by National Natural Science Foundation of China (Grant Numbers: 81673247 & 81773527) and China- Australia International Collaborative Grant (NSFC 81561128020, NHMRC APP1112767). HW and XW were supported by the China Scholarship Council (CSC 201708110200 and CSC 201608230108).

Grant Number

NHMRC Number : APP1112767

Comments

This is a post-peer-review, pre-copyedit version of an article published in EPMA Journal. The final authenticated version is available online at: https://doi.org/10.1007/s13167-020-00200-7

Wang, H., Tian, Q., Zhang, J., Liu, H., Zhang, X., Cao, W., ... & Wang, W. (2020). Population-based case-control study revealed metabolomic biomarkers of suboptimal health status in Chinese population—potential utility for innovative approach by predictive, preventive, and personalized medicine. EPMA Journal, 11, 147 - 160.

Abstract

Background: Suboptimal health status (SHS) is a subclinical stage of chronic diseases, and the identification of SHS provides an opportunity for the predictive, preventive, and personalized medicine (PPPM) of chronic diseases. Previous studies have reported the associations between metabolic signatures and early signs of chronic diseases. Methods: This study aimed to detect the metabolic biomarkers for the identification of SHS in a case-control study. SHS questionnaire-25 (SHSQ-25) was used in a population-based health survey to measure the SHS levels of participants. The liquid chromatography-mass spectrometry-based untargeted metabolomics analysis was conducted on plasma samples collected from 50 SHS participants and 50 age- and sex-matched healthy controls. Results: After adjusting for the confounders, 24 significantly differential metabolites, such as sphingomyelin, sphingosine, sphinganine, progesterone, pregnanolone, and bilirubin, were identified as the candidate biomarkers for SHS. Pathway analysis revealed that sphingolipid metabolism, taurine metabolism, and steroid hormone biosynthesis are the disturbed metabolic pathways related to SHS. A combination of four metabolic biomarkers (sphingosine, pregnanolone, taurolithocholate sulfate, cervonyl carnitine) can distinguish SHS individuals from the controls with a sensitivity of 94.0%, a specificity of 90.0%, and an area under the receiver operating characteristic curve of 0.977. Conclusion: Plasma metabolites are valuable biomarkers for SHS identification, and meanwhile, SHSQ-25 can be used as an alternative health screening tool in the population-based health survey. SHS-related metabolic disturbances could be detected at the early onset of SHS, and SHS-related metabolites could create a window opportunity for PPPM of chronic diseases.

DOI

10.1007/s13167-020-00200-7

Available for download on Wednesday, March 31, 2021

Share

 
COinS